Budget impact analysis
Estimate how a new strategy changes a payer's spending, using the eligible population, uptake and care it replaces.
Why this level?
not one of the five research areas this hierarchy covers. NHMRC 2009 sourceAffordability is not one of the five research areas this hierarchy covers. A budget impact model has no evidence level on this scale.
Fit
When to use it, and when not to
Use it when
- You need the cash consequences for a payer over a stated period.
- You can describe current care and likely uptake of the new option.
Not when
- You need value for money. Use cost-effectiveness or cost-utility analysis.
- You need a causal treatment effect. Use a randomized trial when feasible. Read: Randomized controlled trial
Before you start
What you need
- The payer and budget boundaryState which services and costs fall inside the budget.
- The eligible population in each yearInclude new patients, people leaving and access restrictions.
- Current and future treatment sharesState how uptake changes the care mix. Count the treatments displaced.
- Net prices and service useInclude treatment, monitoring and downstream care paid within the horizon.
- The budget years and uncertaintyReport annual totals. Vary uptake, price and population in scenarios that reflect local practice.
- The treatment shares describe plausible practice.How to check: Check uptake with local clinicians and service capacity. Shares must account for all eligible people.
- Unit costs apply to the payer.How to check: Use relevant net prices and avoid counting the same resource twice.
- Savings occur within the stated budget period.How to check: Separate immediate outlays from later offsets. Do not spend future savings in the current year.
Plain language
How it works
Build a current-care scenario and a scenario with the new strategy. For each budget year, estimate eligible people, treatment shares and costs paid by the decision maker. Subtract current-care spending from future-care spending.
Include monitoring, displaced care and downstream costs within the budget boundary. Show annual totals and scenarios for uncertain uptake or prices. A favorable health-value result does not guarantee that the payer can fund the initial outlay. Use CHEERS for general economic reporting and ISPOR guidance for the payer, care mixes and annual budget consequences.
Worked example
A worked example
- Setting
- A payer has 1000 eligible people during one year.
- Question
- What if some switch to a new treatment?
- Approach
- Assume 200 people switch. Annual cost per person is $500 for new care and $300 for displaced care. All other spending stays equal.
- Result
- Treat 200 of 1000 people with new care, or 20 in 100. Each costs $200 more, so the annual budget rises by $40000.
- What it means
- This is the net change from switching care. It excludes unmodeled service changes and is not a claim about value for money.
In practice
Recent studies PubMed search · not vetted
Watch out
Common mistakes
The one to remember
Budget impact measures affordability for a named payer and period. It does not establish cost-effectiveness; uptake, eligible population and displaced care can reverse the spending estimate.
- Multiplying the new drug price by every eligible patient.Instead: Use expected uptake and subtract displaced care. Add other relevant costs within the payer's budget.
- Treating long-term health value as current cash savings.Instead: Report spending by year and state when any offset occurs.
Inside Mallard
How Mallard uses this
Plans do not link to this design yet. Mallard has no dedicated sizing form for budget impact analysis.
design.budget_impact, the id a plan cue records.Related Learn pages
Related designs and methods
Evidence
Sources & further reading
- Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States (opens in a new tab) · Ann Intern Med · doi 10.7326/M14-1336
- Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation (opens in a new tab) · Clinicoecon Outcomes Res · doi 10.2147/CEOR.S93641
- Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force (opens in a new tab) · Value Health · doi 10.1016/j.jval.2013.08.2291
- Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations (opens in a new tab) · Value Health · doi 10.1016/j.jval.2021.11.1351